-
(
BrahmerJ
ReckampKL
BaasP
, et al. Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
2015;373:123-135.
doi:10.1056/NEJMoa1504627.26028407)
BrahmerJ
ReckampKL
BaasP
, et al. Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
2015;373:123-135.
doi:10.1056/NEJMoa1504627.26028407
BrahmerJ
ReckampKL
BaasP
, et al. Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
2015;373:123-135.
doi:10.1056/NEJMoa1504627.26028407,
BrahmerJ
ReckampKL
BaasP
, et al. Nivolumab versus docetaxel in advanced
squamous-cell non-small-cell lung cancer. N Engl J Med.
2015;373:123-135.
doi:10.1056/NEJMoa1504627.26028407
-
R.
Herbst,
P.
Baas,
Dong-Wan
Kim,
E.
Felip,
J.
Pérez-Gracia,
Ji-Youn
Han,
J.
Molina,
Joo‐Hang
Kim,
C.
Arvis,
M.
Ahn,
M.
Majem,
M.
Fidler,
G.
Castro,
M.
Garrido,
G.
Lubiniecki,
Shentu
Yue,
E.
Im,
M.
Dolled-Filhart,
E.
Garon
(2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
The Lancet, 387
-
T.
Mok,
Yi‐Long
Wu,
I.
Kudaba,
D.
Kowalski,
B.
Cho,
H.
Turna,
G.
Castro,
V.
Srimuninnimit,
K.
Laktionov,
I.
Bondarenko,
K.
Kubota,
G.
Lubiniecki,
Jin
Zhang,
D.
Kush,
G.
Lopes,
G.
Adamchuk,
M.
Ahn,
A.
Alexandru,
O.
Altundag,
A.
Alyasova,
O.
Andrusenko,
K.
Aoe,
A.
Araújo,
O.
Aren,
O.
Rodriguez,
T.
Ativitavas,
Oscar
Avendano,
F.
Barata,
C.
Barrios,
C.
Beato,
Per
Bergstrom,
D.
Betticher,
L.
Bolotina,
Michiel
Botha,
Sayeuri
Buddu,
C.
Caglevic,
A.
Cardona,
H.
Castro,
F.
Senler,
Carlos
Cerny,
A.
Česas,
G.
Chan,
Jian-hua
Chang,
Gongyan
Chen,
Xi
Chen,
S.
Cheng,
Ying
Cheng,
N.
Cherciu,
C.
Chiu,
S.
Cicėnas,
D.
Ciurescu,
G.
Cohen,
Marcos
Costa,
P.
Danchaivijitr,
F.
Angelis,
S.
Azevedo,
M.
Dediu,
Ts
Deliverski,
P.
Marchi,
Flor
Valles,
Z.
Ding,
Boyan
Doganov,
L.
Dreosti,
R.
Duarte,
Regina
Edusma-Dy,
S.
Emelyanov,
M.
Erman,
Yun
Fan,
L.
Fein,
Jifeng
Feng,
D.
Fenton,
G.
Fernandes,
C.
Ferreira,
F.
Franke,
H.
Freitas,
Y.
Fujisaka,
H.
Galindo,
Christina
Galvez,
D.
Ganea,
N.
Gil,
G.
Girotto,
E.
Goker,
T.
Goksel,
Gonzalo
Aubin,
Luis
Wolff,
H.
Griph,
M.
Gumus,
Jacqueline
Hall,
Greg
Hart,
L.
Havel,
Jianxing
He,
Yong
He,
C.
Hernández,
V.
Hespanhol,
T.
Hirashima,
Chung-man.
Ho,
A.
Horiike,
Y.
Hosomi,
K.
Hotta,
M.
Hou,
S.
How,
T.
Hsia,
Yi
Hu,
M.
Ichiki,
F.
Imamura,
O.
Ivashchuk,
Y.
Iwamoto,
J.
Jaal,
J.
Jassem,
Christa
Jordaan,
R.
Juergens,
D.
Kaen,
E.
Kalinka‐Warzocha,
N.
Karaseva,
B.
Karaszewska,
A.
Każarnowicz,
K.
Kasahara,
N.
Katakami,
T.
Kato,
T.
Kawaguchi,
J.
Kim,
K.
Kishi,
V.
Kolek,
Marchela
Koleva,
P.
Kolman,
L.
Koubková,
R.
Kowalyszyn,
D.
Kowalski,
K.
Koynov,
D.
Ksienski,
T.
Kurata,
G.
Kuusk,
L.
Kuzina,
I.
Laczó,
G.
Ladrera,
K.
Laktionov,
G.
Landers,
S.
Lazarev,
G.
Lerzo,
Krzysztof
Kmak,
Wei
Li,
C.
Liam,
Igor
Lifirenko,
O.
Lipatov,
Xiaoqing
Liu,
Zhe
Liu,
S.
Lo,
Valeria
Lopes,
Karla
Lopez,
Shun
Lu,
G.
Martinengo,
L.
Mas,
M.
Matrosova,
Rumyana
Micheva,
Z.
Milanova,
L.
Miron,
Tony
Mok,
M.
Molina,
S.
Murakami,
Y.
Nakahara,
Tien
Nguyen,
T.
Nishimura,
A.
Ochsenbein,
T.
Ohira,
Ronny
Ohman,
C.
Ong,
G.
Ostoros,
X.
Ouyang,
E.
Ovchinnikova,
O.
Ozyılkan,
L.
Petruželka,
Xuan
Pham,
P.
Picon,
B.
Pikó,
A.
Poltoratsky,
Olga
Ponomarova,
Patrice
Popelkova,
G.
Purkalne,
S.
Qin,
R.
Ramlau,
Bernardo
Rappaport,
Felipe
Rey,
E.
Richardet,
J.
Roubec,
P.
Ruff,
A.
Rusyn,
H.
Saka,
J.
Salas,
Mario
Sandoval,
L.
Santos,
T.
Sawa,
K.
Seetalarom,
M.
Seker,
N.
Seki,
Freddy
Seolwane,
L.
Shepherd,
Sergii
Shevnya,
A.
Shimada,
Y.
Shparyk,
I.
Sinielnikov,
D.
Sirbu,
O.
Smaletz,
João
Soares,
A.
Sookprasert,
G.
Speranza,
V.
Sriuranpong,
Zinaida
Stara,
W.
Su,
S.
Sugawara,
W.
Szpak,
Kazuhisa
Takahashi,
N.
Takigawa,
Hiroshi
Tanaka,
Jerry
Bing,
Q.
Tang,
P.
Taranov,
H.
Tejada,
L.
Tho,
Yoshitaro
Torii,
Dmytro
Trukhyn,
M.
Turdean,
H.
Turna,
G.
Ursol,
J.
Vaňásek,
M.
Varela,
M.
Vallejo,
Luis
Vera,
A.
Victorino,
T.
Vlásek,
I.
Vynnychenko,
Buhai
Wang,
Jie
Wang,
Kai
Wang,
Yilong
Wu,
Kazuhiko
Yamada,
Chih‐Hsin
Yang,
T.
Yokoyama,
T.
Yokoyama,
H.
Yoshioka,
F.
Yumuk,
A.
Zambrano,
J.
Zarbá,
O.
Zarubenkov,
Marius
Žemaitis,
Li
Zhang,
Xin
Zhang,
Jun
Zhao,
Caicun
Zhou,
Jianying
Zhou,
Qing
Zhou,
A.
Zippelius
(2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
The Lancet, 393
-
(2015)
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
-
(2019)
RMS: Regression Modeling Strategies. R Package Version 5.1-3.1
-
(2019)
RMS: Regression Modeling Strategies
-
Eugene
Muchnik,
K.
Loh,
M.
Strawderman,
A.
Magnuson,
S.
Mohile,
Vered
Estrah,
R.
Maggiore
(2019)
Immune Checkpoint Inhibitors in Real‐World Treatment of Older Adults with Non–Small Cell Lung Cancer
Journal of the American Geriatrics Society, 67
-
(
MokTSK
WuYL
KudabaI
, et al. Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell
lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3
trial. Lancet.
2019;393:1819-1830.
doi:10.1016/S0140-6736(18)32409.30955977)
MokTSK
WuYL
KudabaI
, et al. Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell
lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3
trial. Lancet.
2019;393:1819-1830.
doi:10.1016/S0140-6736(18)32409.30955977
MokTSK
WuYL
KudabaI
, et al. Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell
lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3
trial. Lancet.
2019;393:1819-1830.
doi:10.1016/S0140-6736(18)32409.30955977,
MokTSK
WuYL
KudabaI
, et al. Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell
lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3
trial. Lancet.
2019;393:1819-1830.
doi:10.1016/S0140-6736(18)32409.30955977
-
N.
Dubrawsky
(1989)
Cancer statistics
CA: A Cancer Journal for Clinicians, 39
-
(
R Core Team. R: A Language and Environment for Statistical
Computing. Vienna, Austria: R
Foundation for Statistical Computing; 2017. https://www.R-project.org.)
R Core Team. R: A Language and Environment for Statistical
Computing. Vienna, Austria: R
Foundation for Statistical Computing; 2017. https://www.R-project.org.
R Core Team. R: A Language and Environment for Statistical
Computing. Vienna, Austria: R
Foundation for Statistical Computing; 2017. https://www.R-project.org.,
R Core Team. R: A Language and Environment for Statistical
Computing. Vienna, Austria: R
Foundation for Statistical Computing; 2017. https://www.R-project.org.
-
(
BorghaeiH
Paz-AresL
HornL
, et al. Nivolumab versus docetaxel in advanced
nonsquamous non-small-cell lung cancer. N Engl J Med.
2015;373:1627-1639.26412456)
BorghaeiH
Paz-AresL
HornL
, et al. Nivolumab versus docetaxel in advanced
nonsquamous non-small-cell lung cancer. N Engl J Med.
2015;373:1627-1639.26412456
BorghaeiH
Paz-AresL
HornL
, et al. Nivolumab versus docetaxel in advanced
nonsquamous non-small-cell lung cancer. N Engl J Med.
2015;373:1627-1639.26412456,
BorghaeiH
Paz-AresL
HornL
, et al. Nivolumab versus docetaxel in advanced
nonsquamous non-small-cell lung cancer. N Engl J Med.
2015;373:1627-1639.26412456
-
(
YounB
TrikalinosNA
MorV
, et al. Real-world use and survival outcomes
of immune checkpoint inhibitors in older adults with non-small cell lung
cancer. Cancer.
2020;126:978-985.
doi:10.1002/cncr.32624.31943163)
YounB
TrikalinosNA
MorV
, et al. Real-world use and survival outcomes
of immune checkpoint inhibitors in older adults with non-small cell lung
cancer. Cancer.
2020;126:978-985.
doi:10.1002/cncr.32624.31943163
YounB
TrikalinosNA
MorV
, et al. Real-world use and survival outcomes
of immune checkpoint inhibitors in older adults with non-small cell lung
cancer. Cancer.
2020;126:978-985.
doi:10.1002/cncr.32624.31943163,
YounB
TrikalinosNA
MorV
, et al. Real-world use and survival outcomes
of immune checkpoint inhibitors in older adults with non-small cell lung
cancer. Cancer.
2020;126:978-985.
doi:10.1002/cncr.32624.31943163
-
D.
Spigel,
M.
Mccleod,
R.
Jotte,
L.
Einhorn,
L.
Horn,
D.
Waterhouse,
B.
Creelan,
S.
Babu,
N.
Leighl,
J.
Chandler,
F.
Couture,
G.
Keogh,
G.
Goss,
D.
Daniel,
E.
Garon,
L.
Schwartzberg,
R.
Sen,
B.
Korytowsky,
A.
Li,
Nivedita
Aanur,
M.
Hussein
(2019)
Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153).
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
-
(
ToiY
SugawaraS
KawashimaY
, et al. Association of immune-related adverse
events with clinical benefit in patients with advanced non-small-cell lung cancer
treated with nivolumab. Oncologist.
2018;23:1358-1365.29934411)
ToiY
SugawaraS
KawashimaY
, et al. Association of immune-related adverse
events with clinical benefit in patients with advanced non-small-cell lung cancer
treated with nivolumab. Oncologist.
2018;23:1358-1365.29934411
ToiY
SugawaraS
KawashimaY
, et al. Association of immune-related adverse
events with clinical benefit in patients with advanced non-small-cell lung cancer
treated with nivolumab. Oncologist.
2018;23:1358-1365.29934411,
ToiY
SugawaraS
KawashimaY
, et al. Association of immune-related adverse
events with clinical benefit in patients with advanced non-small-cell lung cancer
treated with nivolumab. Oncologist.
2018;23:1358-1365.29934411
-
Cancer statistics, 2019
-
G.
Kichenadasse,
J.
Miners,
A.
Mangoni,
A.
Rowland,
A.
Hopkins,
M.
Sorich
(2019)
Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
JAMA oncology
-
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
-
(
SiegelRL
MillerKD
JemalA.
Cancer statistics, 2019. CA.
2019;69:7-34. doi:10.3322/caac.21551.30620402)
SiegelRL
MillerKD
JemalA.
Cancer statistics, 2019. CA.
2019;69:7-34. doi:10.3322/caac.21551.30620402
SiegelRL
MillerKD
JemalA.
Cancer statistics, 2019. CA.
2019;69:7-34. doi:10.3322/caac.21551.30620402,
SiegelRL
MillerKD
JemalA.
Cancer statistics, 2019. CA.
2019;69:7-34. doi:10.3322/caac.21551.30620402
-
Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer
-
J.
Brahmer,
K.
Reckamp,
P.
Baas,
L.
Crinò,
W.
Eberhardt,
E.
Poddubskaya,
S.
Antonia,
A.
Płużański,
E.
Vokes,
E.
Holgado,
D.
Waterhouse,
N.
Ready,
J.
Gainor,
O.
Frontera,
L.
Havel,
M.
Steins,
M.
Garassino,
J.
Aerts,
M.
Dómine,
L.
Paz-Ares,
M.
Reck,
C.
Baudelet,
C.
Harbison,
B.
Lestini,
D.
Spigel
(2015)
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
The New England journal of medicine, 373 2
-
(
EggermontAMM
KicinskiM
BlankCU
, et al. Association between immune-related
adverse events and recurrence-free survival among patients with stage III melanoma
randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized
clinical trial. JAMA Oncol.
2020:6:519-527. doi:10.1001/jamaoncol.2019.5570.31895407)
EggermontAMM
KicinskiM
BlankCU
, et al. Association between immune-related
adverse events and recurrence-free survival among patients with stage III melanoma
randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized
clinical trial. JAMA Oncol.
2020:6:519-527. doi:10.1001/jamaoncol.2019.5570.31895407
EggermontAMM
KicinskiM
BlankCU
, et al. Association between immune-related
adverse events and recurrence-free survival among patients with stage III melanoma
randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized
clinical trial. JAMA Oncol.
2020:6:519-527. doi:10.1001/jamaoncol.2019.5570.31895407,
EggermontAMM
KicinskiM
BlankCU
, et al. Association between immune-related
adverse events and recurrence-free survival among patients with stage III melanoma
randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized
clinical trial. JAMA Oncol.
2020:6:519-527. doi:10.1001/jamaoncol.2019.5570.31895407
-
Rawad
Elias,
K.
Hartshorn,
O.
Rahma,
N.
Lin,
J.
Snyder-Cappione
(2018)
Aging, immune senescence, and immunotherapy: A comprehensive review.
Seminars in oncology, 45 4
-
D.
Spigel,
M.
McLeod,
M.
Hussein,
D.
Waterhouse,
L.
Einhorn,
L.
Horn,
B.
Creelan,
S.
Babu,
N.
Leighl,
F.
Couture,
J.
Chandler,
G.
Goss,
G.
Keogh,
E.
Garon,
K.
Blankstein,
D.
Daniel,
Mohamed
Mohamed,
A.
Li,
Nivedita
Aanur,
R.
Jotte
(2017)
1297ORandomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)
Annals of Oncology, 28
-
(2017)
Randomized results of fixed-duration (1-yr) vs continuous nivolumab in patients (pts) with advanced non-small cell lung cancer (NSCLC)
-
Y.
Toi,
S.
Sugawara,
Y.
Kawashima,
T.
Aiba,
S.
Kawana,
R.
Saito,
K.
Tsurumi,
Kana
Suzuki,
H.
Shimizu,
J.
Sugisaka,
H.
Ono,
Y.
Domeki,
K.
Terayama,
A.
Nakamura,
S.
Yamanda,
Y.
Kimura,
Y.
Honda
(2018)
Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
The oncologist, 23 11
-
K.
Haratani,
H.
Hayashi,
Y.
Chiba,
K.
Kudo,
K.
Yonesaka,
R.
Kato,
H.
Kaneda,
Y.
Hasegawa,
Kaoru
Tanaka,
M.
Takeda,
K.
Nakagawa
(2017)
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
JAMA Oncology, 4
-
S.
Gettinger,
L.
Horn,
L.
Gandhi,
D.
Spigel,
S.
Antonia,
N.
Rizvi,
J.
Powderly,
R.
Heist,
R.
Carvajal,
D.
Jackman,
L.
Sequist,
David
Smith,
P.
Leming,
D.
Carbone,
M.
Pinder-Schenck,
S.
Topalian,
F.
Hodi,
J.
Sosman,
M.
Sznol,
D.
McDermott,
D.
Pardoll,
V.
Sankar,
C.
Ahlers,
M.
Salvati,
J.
Wigginton,
M.
Hellmann,
G.
Kollia,
A.
Gupta,
J.
Brahmer
(2015)
Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 18
-
(2020)
Real - world use and survival outcomes of immune checkpoint inhibitors in older adults with non - small cell lung
-
(
RizviNA
HellmannMD
SnyderA
, et al. Cancer immunology. Mutational
landscape determines sensitivity to PD-1 blockade in non-small cell lung
cancer. Science.
2015;348:124-128.
doi:10.1126/science.aaa1348.25765070)
RizviNA
HellmannMD
SnyderA
, et al. Cancer immunology. Mutational
landscape determines sensitivity to PD-1 blockade in non-small cell lung
cancer. Science.
2015;348:124-128.
doi:10.1126/science.aaa1348.25765070
RizviNA
HellmannMD
SnyderA
, et al. Cancer immunology. Mutational
landscape determines sensitivity to PD-1 blockade in non-small cell lung
cancer. Science.
2015;348:124-128.
doi:10.1126/science.aaa1348.25765070,
RizviNA
HellmannMD
SnyderA
, et al. Cancer immunology. Mutational
landscape determines sensitivity to PD-1 blockade in non-small cell lung
cancer. Science.
2015;348:124-128.
doi:10.1126/science.aaa1348.25765070
-
(
MuchnikE
LohKP
StrawdermanM
, et al. Immune checkpoint inhibitors in
real-world treatment of older adults with non-small cell lung cancer.
J Am Geriatr Soc.
2019;67:905-912.30698276)
MuchnikE
LohKP
StrawdermanM
, et al. Immune checkpoint inhibitors in
real-world treatment of older adults with non-small cell lung cancer.
J Am Geriatr Soc.
2019;67:905-912.30698276
MuchnikE
LohKP
StrawdermanM
, et al. Immune checkpoint inhibitors in
real-world treatment of older adults with non-small cell lung cancer.
J Am Geriatr Soc.
2019;67:905-912.30698276,
MuchnikE
LohKP
StrawdermanM
, et al. Immune checkpoint inhibitors in
real-world treatment of older adults with non-small cell lung cancer.
J Am Geriatr Soc.
2019;67:905-912.30698276
-
(2017)
A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2017
-
(
ReckM
Rodriguez-AbreuD
RobinsonAG
, et al. Pembrolizumab versus chemotherapy for
PD-L1-positive non-small-cell lung cancer. N Engl J
Med.
2016;375:1823-1833.
doi:10.1056/NEJMoa1606774.27718847)
ReckM
Rodriguez-AbreuD
RobinsonAG
, et al. Pembrolizumab versus chemotherapy for
PD-L1-positive non-small-cell lung cancer. N Engl J
Med.
2016;375:1823-1833.
doi:10.1056/NEJMoa1606774.27718847
ReckM
Rodriguez-AbreuD
RobinsonAG
, et al. Pembrolizumab versus chemotherapy for
PD-L1-positive non-small-cell lung cancer. N Engl J
Med.
2016;375:1823-1833.
doi:10.1056/NEJMoa1606774.27718847,
ReckM
Rodriguez-AbreuD
RobinsonAG
, et al. Pembrolizumab versus chemotherapy for
PD-L1-positive non-small-cell lung cancer. N Engl J
Med.
2016;375:1823-1833.
doi:10.1056/NEJMoa1606774.27718847
-
R.
Pirker
(2018)
Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?
ESMO Open, 3
-
R.
Siegel,
K.
Miller,
A.
Jemal
(2019)
Cancer statistics, 2019
CA: A Cancer Journal for Clinicians, 69
-
N.
Rizvi,
M.
Hellmann,
A.
Snyder,
P.
Kvistborg,
V.
Makarov,
J.
Havel,
William
Lee,
Jianda
Yuan,
P.
Wong,
Teresa
Ho,
Martin
Miller,
N.
Rekhtman,
A.
Moreira,
Fawzia
Ibrahim,
Cameron
Bruggeman,
Billel
Gasmi,
R.
Zappasodi,
Y.
Maeda,
C.
Sander,
E.
Garon,
T.
Merghoub,
J.
Wolchok,
T.
Schumacher,
T.
Chan
(2015)
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Science, 348
-
Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer
-
(
KleinJP
MoeschbergerML.
Survival Analysis: Techniques for Censored and Truncated Data.
2nd ed.
New York: Springer-Verlag;
2003.)
KleinJP
MoeschbergerML.
Survival Analysis: Techniques for Censored and Truncated Data.
2nd ed.
New York: Springer-Verlag;
2003.
KleinJP
MoeschbergerML.
Survival Analysis: Techniques for Censored and Truncated Data.
2nd ed.
New York: Springer-Verlag;
2003.,
KleinJP
MoeschbergerML.
Survival Analysis: Techniques for Censored and Truncated Data.
2nd ed.
New York: Springer-Verlag;
2003.
-
(
SpigelDR
McCleodM
JotteRM
, et al. Safety, efficacy, and patient-reported
health-related quality of life and symptom burden with nivolumab in patients with
advanced non-small cell lung cancer, including patients aged 70 years or older or with
poor performance status (CheckMate 153). J Thorac
Oncol.
2019;14:1628-1639.31121324)
SpigelDR
McCleodM
JotteRM
, et al. Safety, efficacy, and patient-reported
health-related quality of life and symptom burden with nivolumab in patients with
advanced non-small cell lung cancer, including patients aged 70 years or older or with
poor performance status (CheckMate 153). J Thorac
Oncol.
2019;14:1628-1639.31121324
SpigelDR
McCleodM
JotteRM
, et al. Safety, efficacy, and patient-reported
health-related quality of life and symptom burden with nivolumab in patients with
advanced non-small cell lung cancer, including patients aged 70 years or older or with
poor performance status (CheckMate 153). J Thorac
Oncol.
2019;14:1628-1639.31121324,
SpigelDR
McCleodM
JotteRM
, et al. Safety, efficacy, and patient-reported
health-related quality of life and symptom burden with nivolumab in patients with
advanced non-small cell lung cancer, including patients aged 70 years or older or with
poor performance status (CheckMate 153). J Thorac
Oncol.
2019;14:1628-1639.31121324
-
(
EliasR
HartshornK
RahmaO
LinN
Snyder-CappioneJE.
Aging, immune senescence, and immunotherapy: a comprehensive
review. Semin Oncol.
2018;45:187-200.30539714)
EliasR
HartshornK
RahmaO
LinN
Snyder-CappioneJE.
Aging, immune senescence, and immunotherapy: a comprehensive
review. Semin Oncol.
2018;45:187-200.30539714
EliasR
HartshornK
RahmaO
LinN
Snyder-CappioneJE.
Aging, immune senescence, and immunotherapy: a comprehensive
review. Semin Oncol.
2018;45:187-200.30539714,
EliasR
HartshornK
RahmaO
LinN
Snyder-CappioneJE.
Aging, immune senescence, and immunotherapy: a comprehensive
review. Semin Oncol.
2018;45:187-200.30539714
-
(
GettingerSN
HornL
GandhiL
, et al. Overall survival and long-term safety
of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with
previously treated advanced non-small-cell lung cancer. J Clin
Oncol.
2015;33:2004-2012.
doi:10.1200/JCO.2014.58.3708.25897158)
GettingerSN
HornL
GandhiL
, et al. Overall survival and long-term safety
of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with
previously treated advanced non-small-cell lung cancer. J Clin
Oncol.
2015;33:2004-2012.
doi:10.1200/JCO.2014.58.3708.25897158
GettingerSN
HornL
GandhiL
, et al. Overall survival and long-term safety
of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with
previously treated advanced non-small-cell lung cancer. J Clin
Oncol.
2015;33:2004-2012.
doi:10.1200/JCO.2014.58.3708.25897158,
GettingerSN
HornL
GandhiL
, et al. Overall survival and long-term safety
of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with
previously treated advanced non-small-cell lung cancer. J Clin
Oncol.
2015;33:2004-2012.
doi:10.1200/JCO.2014.58.3708.25897158
-
A.
Eggermont,
M.
Kicinski,
C.
Blank,
M.
Mandalà,
G.
Long,
V.
Atkinson,
S.
Dalle,
A.
Haydon,
A.
Khattak,
M.
Carlino,
S.
Sandhu,
J.
Larkin,
S.
Puig,
P.
Ascierto,
P.
Rutkowski,
D.
Schadendorf,
R.
Koornstra,
L.
Hernandez-Aya,
A.
Giacomo,
A.
Eertwegh,
J.
Grob,
R.
Gutzmer,
R.
Jamal,
P.
Lorigan,
C.
Krepler,
N.
Ibrahim,
S.
Marréaud,
A.
Akkooi,
C.
Robert,
S.
Suciu
(2020)
Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo
JAMA Oncology, 6
-
(
KichenadasseG
MinersJO
MangoniAA
, et al. Association between body mass index
and overall survival with immune checkpoint inhibitor therapy for advanced non-small
cell lung cancer. JAMA Oncol.
2020;6:512-518. doi:10.1001/jamaoncol.2019.5241.31876896)
KichenadasseG
MinersJO
MangoniAA
, et al. Association between body mass index
and overall survival with immune checkpoint inhibitor therapy for advanced non-small
cell lung cancer. JAMA Oncol.
2020;6:512-518. doi:10.1001/jamaoncol.2019.5241.31876896
KichenadasseG
MinersJO
MangoniAA
, et al. Association between body mass index
and overall survival with immune checkpoint inhibitor therapy for advanced non-small
cell lung cancer. JAMA Oncol.
2020;6:512-518. doi:10.1001/jamaoncol.2019.5241.31876896,
KichenadasseG
MinersJO
MangoniAA
, et al. Association between body mass index
and overall survival with immune checkpoint inhibitor therapy for advanced non-small
cell lung cancer. JAMA Oncol.
2020;6:512-518. doi:10.1001/jamaoncol.2019.5241.31876896
-
Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer
-
James
Helmreich
(2016)
Regression Modeling Strategies with Applications to Linear Models, Logistic and Ordinal Regression and Survival Analysis (2nd Edition)
Journal of Statistical Software, 70
-
(
HerbstRS
BaasP
KimDW
, et al. Pembrolizumab versus docetaxel for
previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a
randomised controlled trial. Lancet.
2016;387:1540-1550.
doi:10.1016/S0140-6736(15)01281.26712084)
HerbstRS
BaasP
KimDW
, et al. Pembrolizumab versus docetaxel for
previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a
randomised controlled trial. Lancet.
2016;387:1540-1550.
doi:10.1016/S0140-6736(15)01281.26712084
HerbstRS
BaasP
KimDW
, et al. Pembrolizumab versus docetaxel for
previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a
randomised controlled trial. Lancet.
2016;387:1540-1550.
doi:10.1016/S0140-6736(15)01281.26712084,
HerbstRS
BaasP
KimDW
, et al. Pembrolizumab versus docetaxel for
previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a
randomised controlled trial. Lancet.
2016;387:1540-1550.
doi:10.1016/S0140-6736(15)01281.26712084
-
Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer
-
Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial
-
(
HarataniK
HayashiH
ChibaY
, et al. Association of immune-related adverse
events with nivolumab efficacy in non-small-cell lung cancer.
JAMA Oncol.
2018;4:374-378. doi:10.1001/jamaoncol.2017.2925.28975219)
HarataniK
HayashiH
ChibaY
, et al. Association of immune-related adverse
events with nivolumab efficacy in non-small-cell lung cancer.
JAMA Oncol.
2018;4:374-378. doi:10.1001/jamaoncol.2017.2925.28975219
HarataniK
HayashiH
ChibaY
, et al. Association of immune-related adverse
events with nivolumab efficacy in non-small-cell lung cancer.
JAMA Oncol.
2018;4:374-378. doi:10.1001/jamaoncol.2017.2925.28975219,
HarataniK
HayashiH
ChibaY
, et al. Association of immune-related adverse
events with nivolumab efficacy in non-small-cell lung cancer.
JAMA Oncol.
2018;4:374-378. doi:10.1001/jamaoncol.2017.2925.28975219
-
B.
Youn,
N.
Trikalinos,
V.
Mor,
I.
Wilson,
I.
Dahabreh
(2020)
Real‐world use and survival outcomes of immune checkpoint inhibitors in older adults with non–small cell lung cancer
Cancer, 126
-
(
HarrellFE.
RMS: Regression Modeling Strategies. R Package Version 5.1-3.1; 2019.
https://CRAN.R-project.org/package=rms.)
HarrellFE.
RMS: Regression Modeling Strategies. R Package Version 5.1-3.1; 2019.
https://CRAN.R-project.org/package=rms.
HarrellFE.
RMS: Regression Modeling Strategies. R Package Version 5.1-3.1; 2019.
https://CRAN.R-project.org/package=rms.,
HarrellFE.
RMS: Regression Modeling Strategies. R Package Version 5.1-3.1; 2019.
https://CRAN.R-project.org/package=rms.
-
Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
-
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
-
M.
Reck,
D.
Rodríguez-Abreu,
A.
Robinson,
R.
Hui,
T.
Csőszi,
A.
Fülöp,
M.
Gottfried,
N.
Peled,
A.
Tafreshi,
S.
Cuffe,
M.
O'Brien,
Suman
Rao,
K.
Hotta,
M.
Leiby,
G.
Lubiniecki,
Shentu
Yue,
Reshma
Rangwala,
J.
Brahmer
(2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
The New England journal of medicine, 375 19
-
R.
Team
(2014)
R: A language and environment for statistical computing.
MSOR connections, 1
-
A.
Rittmeyer,
F.
Barlesi,
D.
Waterkamp,
Keunchil
Park,
F.
Ciardiello,
J.
Pawel,
S.
Gadgeel,
T.
Hida,
D.
Kowalski,
M.
Dols,
D.
Cortinovis,
J.
Leach,
J.
Polikoff,
C.
Barrios,
F.
Kabbinavar,
O.
Frontera,
F.
Marinis,
H.
Turna,
Jong-Seok
Lee,
M.
Ballinger,
M.
Kowanetz,
P.
He,
Daniel
Chen,
A.
Sandler,
D.
Gandara
(2017)
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
The Lancet, 389
-
Ziming
Wang,
Ethan
Aguilar,
Jesus
Luna,
C.
Dunai,
Lam
Khuat,
Catherine
Le,
Annie
Mirsoian,
Christine
Minnar,
Kevin
Stoffel,
Ian
Sturgill,
S.
Grossenbacher,
S.
Withers,
R.
Rebhun,
D.
Hartigan-O’Connor,
Gema
Méndez-Lagares,
A.
Tarantal,
R.
Isseroff,
T.
Griffith,
K.
Schalper,
A.
Merleev,
A.
Saha,
E.
Maverakis,
K.
Kelly,
R.
Aljumaily,
S.
Ibrahimi,
S.
Mukherjee,
M.
Machiorlatti,
S.
Vesely,
D.
Longo,
B.
Blazar,
R.
Canter,
W.
Murphy,
A.
Monjazeb
(2018)
Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade
Nature medicine, 25
-
H.
Borghaei,
L.
Paz-Ares,
L.
Horn,
D.
Spigel,
M.
Steins,
N.
Ready,
L.
Chow,
E.
Vokes,
E.
Felip,
E.
Holgado,
F.
Barlesi,
M.
Kohlhäufl,
O.
Arrieta,
M.
Burgio,
J.
Fayette,
H.
Léna,
E.
Poddubskaya,
D.
Gerber,
S.
Gettinger,
C.
Rudin,
N.
Rizvi,
L.
Crinò,
G.
Blumenschein,
S.
Antonia,
C.
Dorange,
C.
Harbison,
F.
Finckenstein,
J.
Brahmer
(2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
The New England journal of medicine, 373 17
-
(
RittmeyerA
BarlesiF
WaterkampD
, et al. Atezolizumab versus docetaxel in
patients with previously treated non-small-cell lung cancer (OAK): a phase 3,
open-label, multicentre randomised controlled trial. The
Lancet.
2017;389:255-265.)
RittmeyerA
BarlesiF
WaterkampD
, et al. Atezolizumab versus docetaxel in
patients with previously treated non-small-cell lung cancer (OAK): a phase 3,
open-label, multicentre randomised controlled trial. The
Lancet.
2017;389:255-265.
RittmeyerA
BarlesiF
WaterkampD
, et al. Atezolizumab versus docetaxel in
patients with previously treated non-small-cell lung cancer (OAK): a phase 3,
open-label, multicentre randomised controlled trial. The
Lancet.
2017;389:255-265.,
RittmeyerA
BarlesiF
WaterkampD
, et al. Atezolizumab versus docetaxel in
patients with previously treated non-small-cell lung cancer (OAK): a phase 3,
open-label, multicentre randomised controlled trial. The
Lancet.
2017;389:255-265.
-
(
WangZ
AguilarEG
LunaJI
, et al. Paradoxical effects of obesity on T
cell function during tumor progression and PD-1 checkpoint blockade.
Nat Med.
2019;25:141-151.30420753)
WangZ
AguilarEG
LunaJI
, et al. Paradoxical effects of obesity on T
cell function during tumor progression and PD-1 checkpoint blockade.
Nat Med.
2019;25:141-151.30420753
WangZ
AguilarEG
LunaJI
, et al. Paradoxical effects of obesity on T
cell function during tumor progression and PD-1 checkpoint blockade.
Nat Med.
2019;25:141-151.30420753,
WangZ
AguilarEG
LunaJI
, et al. Paradoxical effects of obesity on T
cell function during tumor progression and PD-1 checkpoint blockade.
Nat Med.
2019;25:141-151.30420753
-
Rawad
Elias,
T.
Karantanos,
Elizabeth
Sira,
K.
Hartshorn
(2017)
Immunotherapy comes of age: Immune aging & checkpoint inhibitors.
Journal of geriatric oncology, 8 3
-
Jun
Yan
(2004)
Survival Analysis: Techniques for Censored and Truncated Data
Journal of the American Statistical Association, 99
-
(
PirkerR.
Is smoking history the truly best biomarker for immune checkpoint inhibitor
treatment in advanced non-small cell lung cancer. ESMO
Open.
2018;3:e000421.30116594)
PirkerR.
Is smoking history the truly best biomarker for immune checkpoint inhibitor
treatment in advanced non-small cell lung cancer. ESMO
Open.
2018;3:e000421.30116594
PirkerR.
Is smoking history the truly best biomarker for immune checkpoint inhibitor
treatment in advanced non-small cell lung cancer. ESMO
Open.
2018;3:e000421.30116594,
PirkerR.
Is smoking history the truly best biomarker for immune checkpoint inhibitor
treatment in advanced non-small cell lung cancer. ESMO
Open.
2018;3:e000421.30116594